Vermont Sen. Bernie Sanders has canceled a Senate committee vote that would have determined whether to subpoena Novo Nordisk executives about the cost of the drugmaker’s blockbuster drugs, Ozempic and Wegovy. The move comes as Novo Nordisk’s CEO agreed to participate in a Senate committee hearing set for September.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
